Climb Bio, Inc. (CLYM)
CLYM Stock Price Chart
Explore Climb Bio, Inc. interactive price chart. Choose custom timeframes to analyze CLYM price movements and trends.
CLYM Company Profile
Discover essential business fundamentals and corporate details for Climb Bio, Inc. (CLYM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
10 Aug 2021
Employees
17.00
Website
https://eliemtx.comCEO
Aoife Brennan BCh MMSc
Description
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.
CLYM Financial Timeline
Browse a chronological timeline of Climb Bio, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
CLYM Stock Performance
Access detailed CLYM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
